retatrutide phase 2 nejm 2023 percent weight loss 48 weeks This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist for Obesity — A Trial https://t.co/jNL1GNnHPT #Endocrinology 2023年度回顧】 NEJM Notable Articles of

This hair loss is likely linked to telogen effluvium, a temporary condition caused by stress on the body, rather than a direct effect of the medication itself

Other drugmakers including Amgen, Boehringer Ingelheim, and Novo Nordisk are working on multi-receptor candidates of their own, which suggests that triple- and even four-receptor designs are likely the future of obesity pharmacology.[4] What makes retatrutide different from drugs already on the market is that it works on three of your body's natural appetite and metabolism signals at the same time

Saxenda was the first to be approved in 2014, followed by Wegovy in 2020 and Zepbound in 2023

In this way, microdosing could individualize therapy, much like precision medicine strategies in other fields

There is a bidirectional relationship between gastric emptying and post-meal glucose levels irrespective of the presence of diabetes

This can be OK for some people who may respond well and not need a more potent drug, or those with less body fat to lose